Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frespaciguat in COVID-19 Pneumonia
NCT04425733Phase 1Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of frespaciguat in COVID-19 pneumonia (6 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinued Study Drug Due to an Adverse Event (AE) and 1 more. Planned start Jul 2020; status: withdrawn.
02
Drugs
frespaciguat
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04425733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425733.